News Ocugen, Histogenics merge to form eye disease specialist US biotechs Ocugen and Histogenics have announced plans to merge, creating a specialist in drugs and gene therapies for ocular diseases.
News In shock move, EU panel rejects Alzheimer's drug Leqembi The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh
Sales & Marketing Sponsored How doctors are interacting with content in 10 data trends It will come as no surprise to anyone in the healthcare space that doctors today are under an inordinate amount of pressure.